Compass Therapeutics’ (CMPX) “Buy” Rating Reiterated at D. Boral Capital
D. Boral Capital reaffirmed their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX – Free Report) in a report published on Tuesday,Benzinga reports. The firm currently has a $32.00 price ...
kalkinemedia9h
Can Maze Therapeutics Transform Genetic Medicine?
Highlights,Maze Therapeutics is a clinical-stage biopharmaceutical company focused on precision medicines for renal, ...
Maze Therapeutics (NASDAQ:MAZE) Upgraded at Leerink Partnrs
Leerink Partnrs upgraded shares of Maze Therapeutics (NASDAQ:MAZE – Free Report) to a strong-buy rating in a report released ...
Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the fourth quarter and year ended December 31, 2024, and ...
Psychedelic: GH Research, Compass Pathways report earnings results
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, an analyst ...